Blinded Comparator Study of Immunohistochemical Analysis versus a 92-Gene Cancer Classifier in the Diagnosis of the Primary Site in Metastatic Tumors

Blinded Comparator Study of Immunohistochemical Analysis versus a 92-Gene Cancer Classifier in the Diagnosis of the Primary Site in Metastatic Tumors

Accurate tumor classification is fundamental to inform predictive biomarker testing and optimize therapy. Gene expression–based tests are proposed as diagnostic aids in cases with uncertain diagnoses. This study directly compared the diagnostic accuracy of IHC analysis versus molecular classification using a 92-gene RT-PCR assay for determination of the primary tumor site.1

Available free online from The Journal of Molecular Diagnostics.

1. Weiss LM et al. J Mol Diagn. 2013;15(2):263-269.

Download